VitaK has a substantial investment program to increase its own clinical equipment for in-house clinical endpoint measurements in human intervention trials and clinical trials.
Worldwide we are the number one laboratory in measuring Matrix Gla Protein (MGP).
VitaK Innovation in Life Science has a strong focus on the development of new Point of Care and In Vitro Diagnostic tests.
What if you could identify high risk patients at the earliest stage of their cardiovascular disease?
VitaK has its own facilities for blood sampling and measuring clinical endpoints in the various human intervention trials that are executed.
Both fundamental and applied research are the core business of VitaK. We offer our expertise in the form of contract research for third parties.
The POC testing market is set to reach $49 billion by 2018.

VitaK has a substantial investment program to increase its own clinical equipment for in-house clinical endpoint measurements in human intervention trials and clinical trials.

Worldwide we are the number one laboratory in measuring Matrix Gla Protein (MGP).

VitaK Innovation in Life Science has a strong focus on the development of new Point of Care and In Vitro Diagnostic tests.

What if you could identify high risk patients at the earliest stage of their cardiovascular disease?

VitaK has its own facilities for blood sampling and measuring clinical endpoints in the various human intervention trials that are executed.

Both fundamental and applied research are the core business of VitaK. We offer our expertise in the form of contract research for third parties.

The POC testing market is set to reach $49 billion by 2018.

VitaK is a world-leading provider of laboratory services with its own R&D department specialized in developing and manufacturing high-quality innovative medical devices. Our scientists are devoted researchers with an impressive track record, and they address upcoming clinical and economic needs through applied research and innovative technology. The POC testing market is set to reach $49 billion by 2018 and is growing in all major segments: hospitals, ambulatory care settings, physician offices and the home. The market is forecasted to grow at a 10.9% average annual growth rate.

Head office:
Oxfordlaan 55
6229 EV Maastricht
The Netherlands
T: +31 (0)43 388 5926

Laboratories:
Oxfordlaan 70
6229 EV Maastricht
The Netherlands
E: info@vitak.com